Get the latest news, insights, and market updates on GH (Guardant Health, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
1 Growth Stock Set to Flourishand 2 We Avoid
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. Jan 2, 2026 - $GH
Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside
Guardant Health Inc. (NASDAQ:GH) is one of the hottest large-cap stocks of 2025. On December 22, Canaccord raised the firm’s price target on Guardant Health to $125 from $100 with a Buy rating on the shares. The firm expects the life science sector to maintain its current upward trend well into 2026. Guardant Health remains […] Dec 31, 2025 - $GH
Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens
Medical stocks as a whole faced rough waters entering 2025, but market rotation is among the factors pushing up stock prices throughout the health industry as the year winds down. Such gains and other fundamental considerations have led medical companies like Guardant Health onto the IBD 50 list of top growth stocks. Others on the list include PACS Group, Natera and Nutex . Dec 26, 2025 - $GH
Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth
We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Guardant Health, Inc. is one of the most promising stocks. TheFly reported on December 17 that Mizuho analyst Anthony Petrone maintained an Outperform rating on GH and raised the price target to $120 from $100, reflecting growing confidence in […] Dec 23, 2025 - $GH
Guardant Health price target raised to $120 from $100 at BofA
BofA raised the firm’s price target on Guardant Health (GH) to $120 from $100 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and Dec 16, 2025 - $GH
Guardant Health (GH): Reassessing Valuation After a Sharp Share Price Recovery
Why Guardant Health Is Back On Investors Radar Guardant Health (GH) has quietly staged a sharp comeback, with the stock more than doubling over the past year, as investors focus on its role in precision oncology and its recent financial performance. See our latest analysis for Guardant Health. The latest share price of $102.07 reflects a powerful shift in sentiment, with an 86 percent 90 day share price return and a 193 percent 1 year total shareholder return signaling strong upward momentum... Dec 14, 2025 - $GH
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
PALO ALTO, Calif. & ROME, December 09, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreakin Dec 9, 2025 - $GH
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple